Select the category to fetch information by relevance.
Contributed By Vidyasagar K
This article examines common Good Clinical Practice (GCP) violations in clinical trials, identifying potential consequences and emphasizing the importance of adherence to ethical and regulatory standards. The discussion covers issues such as inadequate informed consent processes, insufficient regulatory documentation, and problems related to monitoring and oversight. Data integrity and documentation issues, protocol deviations, and conflicts of interest are also explored. By highlighting these common violations, the article underscores the critical need for rigorous adherence to GCP guidelines to ensure the credibility, reliability, and ethical foundation of clinical trial outcomes. Clinical trials are integral to medical advancements, yet they are fraught with regulatory complexities, particularly in the realm of Good Clinical Practice (GCP). This article delves into the common GCP violations encountered in clinical trials, from issues with informed consent and inadequate monitoring to data integrity concerns. By recognizing these pitfalls, the pharmaceutical and research community can proactively address challenges, fortify compliance, and elevate the ethical standards of clinical research.